Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

, MRK

Merck

09:13
10/10/16
10/10
09:13
10/10/16
09:13

JPMorgan Euro & US pharma/biotech analysts hold analyst/industry conference call

European Healthcare Analysts Vosser and Gordon, along with U.S. and Specialty Pharmaceuticals Analyst Schott, discuss key takeaways from the European Society for Medical Oncology (ESMO) Conference on an Analyst/Industry conference call to be held on October 10 at 10 am.

BMY

Bristol-Myers

MRK

Merck

RHHBY

Roche

$30.49

-0.05 (-0.16%)

AZN

AstraZeneca

  • 19

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 16

    Nov

BMY Bristol-Myers

09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
MRK Merck

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
RHHBY Roche
$30.49

-0.05 (-0.16%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
AZN AstraZeneca

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas

TODAY'S FREE FLY STORIES

ELLO

Ellomay Capital

$8.05

0.0019 (0.02%)

14:33
04/30/17
04/30
14:33
04/30/17
14:33
Hot Stocks
Ellomay Capital enters agreement to acquire Talasol Solar »

Ellomay Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$86.86

0.87 (1.01%)

14:23
04/30/17
04/30
14:23
04/30/17
14:23
Hot Stocks
Galapagos presents preclinical data on osteoarthritis candidate GLPG1972 »

Galapagos announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

SO

Southern Company

$49.80

-0.27 (-0.54%)

, TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

14:16
04/30/17
04/30
14:16
04/30/17
14:16
Hot Stocks
Southern Co subsidiary extends interim agreement for Vogtle nuclear expansion »

Georgia Power and…

SO

Southern Company

$49.80

-0.27 (-0.54%)

TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

TOSYY

Toshiba, also use TOSBF

$12.14

0.25 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

CG

Carlyle Group

$17.70

0.2 (1.14%)

14:10
04/30/17
04/30
14:10
04/30/17
14:10
Hot Stocks
Sequa completes recapitalization with participation from Carlyle Group »

Sequa Corp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$160.29

-0.03 (-0.02%)

14:07
04/30/17
04/30
14:07
04/30/17
14:07
Hot Stocks
IBM says granted patent for drone package transfer »

IBM announced Friday that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRAM

Grana y Montero

$3.37

0.07 (2.12%)

14:05
04/30/17
04/30
14:05
04/30/17
14:05
Hot Stocks
Grana y Montero completes sale of PRINSUR stake for $25M »

Grana y Montero announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.15

0.14 (0.33%)

13:49
04/30/17
04/30
13:49
04/30/17
13:49
Hot Stocks
Coca-Cola Bottling UNITED says closes Georgia transaction with Coca-Cola »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

VZ

Verizon

$45.91

-0.76 (-1.63%)

, T

AT&T

$39.63

-0.28 (-0.70%)

13:06
04/30/17
04/30
13:06
04/30/17
13:06
Periodicals
Business tax cut would favor telecoms, retailers, other sectors, Barron's says »

Sectors favored under a…

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

JPM

JPMorgan

$87.00

-0.61 (-0.70%)

COF

Capital One

$80.38

-1.93 (-2.34%)

CMA

Comerica

$70.70

-0.05 (-0.07%)

GPS

Gap

$26.20

-0.15 (-0.57%)

JWN

Nordstrom

$48.27

-0.03 (-0.06%)

BRK.A

Berkshire Hathaway

$247,780.00

-2170 (-0.87%)

BRK.B

Berkshire Hathaway

$165.21

-1.34 (-0.80%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 09

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

CMG

Chipotle

$474.47

-7.53 (-1.56%)

12:59
04/30/17
04/30
12:59
04/30/17
12:59
Periodicals
Chipotle remains unattractive, Barron's says »

Investors should continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

, ANTM

Anthem

$177.89

-0.41 (-0.23%)

12:45
04/30/17
04/30
12:45
04/30/17
12:45
Periodicals
Express Scripts contract-loss warning suggests further pain, Barron's says »

Express Scripts'…

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CVS

CVS Health

$82.44

-0.35 (-0.42%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

LITE

Lumentum

$42.75

-1.05 (-2.40%)

, OCLR

Oclaro

$8.01

0.08 (1.01%)

12:38
04/30/17
04/30
12:38
04/30/17
12:38
Periodicals
Bargain-priced fiberoptic space looks attractive, Barron's says »

Fiberoptic stocks…

LITE

Lumentum

$42.75

-1.05 (-2.40%)

OCLR

Oclaro

$8.01

0.08 (1.01%)

NPTN

NeoPhotonics

$7.76

-0.19 (-2.39%)

FNSR

Finisar

$22.84

0.27 (1.20%)

ACIA

Acacia Communications

$45.84

-0.76 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 04

    May

  • 05

    May

  • 09

    May

  • 09

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 30

    May

COH

Coach

$39.39

-0.43 (-1.08%)

12:14
04/30/17
04/30
12:14
04/30/17
12:14
Periodicals
Coach could reserve course, Barron's says »

Retail accessory makers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

, PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

12:08
04/30/17
04/30
12:08
04/30/17
12:08
Periodicals
Bargain-priced Edgewell could attract suitor, Barron's says »

Edgewell Personal Care…

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NEE

NextEra Energy

$133.56

0.04 (0.03%)

11:58
04/30/17
04/30
11:58
04/30/17
11:58
Periodicals
NextEra Energy could return 20% in a year, Barron's says »

NextEra Energy appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CAT

Caterpillar

$102.26

-0.42 (-0.41%)

11:52
04/30/17
04/30
11:52
04/30/17
11:52
Periodicals
Caterpillar shares 'back on track' for price gains, Barron's says »

Caterpillar is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

RYN

Rayonier

$28.22

-0.39 (-1.36%)

, LL

Lumber Liquidators

$24.55

0.19 (0.78%)

08:21
04/30/17
04/30
08:21
04/30/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

RYN

Rayonier

$28.22

-0.39 (-1.36%)

LL

Lumber Liquidators

$24.55

0.19 (0.78%)

DEL

Deltic Timber

$77.37

-2.24 (-2.81%)

WY

Weyerhaeuser

$33.87

-0.8 (-2.31%)

OSB

Norbord

$31.07

0.23 (0.75%)

PCH

Potlatch

$45.05

-1.9 (-4.05%)

UFPI

Universal Forest

$95.29

-1.92 (-1.98%)

AA

Alcoa

$33.73

-0.79 (-2.29%)

KALU

Kaiser Aluminum

$84.41

-0.15 (-0.18%)

CENX

Century Aluminum

$13.64

-0.36 (-2.57%)

NFLX

Netflix

$152.20

-0.88 (-0.57%)

FB

Facebook

$150.25

2.55 (1.73%)

AMZN

Amazon.com

$924.99

6.61 (0.72%)

GOOG

Alphabet

$905.96

31.71 (3.63%)

GOOGL

Alphabet Class A

$924.52

33.08 (3.71%)

CMCSA

Comcast

$39.19

-0.4 (-1.01%)

CMCSK

Comcast

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

CYH

Community Health

$8.61

0.18 (2.14%)

HCA

HCA Holdings

$84.21

0.77 (0.92%)

LPNT

LifePoint

$62.15

1.4 (2.30%)

THC

Tenet

$15.67

0.2 (1.29%)

UHS

Universal Health

$120.76

2.55 (2.16%)

AET

Aetna

$135.07

1.09 (0.81%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CNC

Centene

$74.40

1.45 (1.99%)

CI

Cigna

$156.37

0.16 (0.10%)

HNT

Health Net

HUM

Humana

$221.98

3.31 (1.51%)

MOH

Molina Healthcare

$49.79

1.16 (2.39%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

WCG

WellCare

$153.41

0.03 (0.02%)

HRB

H&R Block

$24.79

0.52 (2.14%)

INTU

Intuit

$125.21

-0.4 (-0.32%)

ATW

Atwood Oceanics

$7.83

-0.01 (-0.13%)

DO

Diamond Offshore

$14.42

-0.07 (-0.48%)

NE

Noble Corp.

$4.80

-0.03 (-0.62%)

NADL

North Atlantic Drilling

$2.53

0.18 (7.66%)

PACD

Pacific Drilling

$1.70

-0.07 (-3.95%)

RDC

Rowan Companies

$14.07

0.07 (0.50%)

SDRL

Seadrill

$0.69

0.0221 (3.31%)

FSLR

First Solar

$29.55

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 05

    May

  • 05

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Jun

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.